Although the mechanistic link between mutations/polymorphisms in ADRB3 and metabolic disease in humans remains to be established (87), it will be important to determine whether administration of a β3-AR agonist could be used to treat these conditions. This evidence concerns the gene ADRB3 and Other metabolic disease.